Fasting induces prominent proteomic changes in liver in very long chain Acyl-CoA dehydrogenase deficient mice  by Wang, Wei et al.
Contents lists available at ScienceDirect
Biochemistry and Biophysics Reports
journal homepage: www.elsevier.com/locate/bbrep
Fasting induces prominent proteomic changes in liver in very long chain
Acyl-CoA dehydrogenase deﬁcient mice
Wei Wanga,b,⁎, Johan Palmfeldtc, Al-Walid Mohsend, Niels Gregersenc, Jerry Vockleyb,d
a Department of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiaotong University, Shanghai, China
b Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, USA
c Research Unit for Molecular Medicine, Institute of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
d Department of Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, USA
A R T I C L E I N F O
Keywords:
VLCAD deﬁciency
β-oxidation
Oxidative phosphorylation
Proteomics
HSP60
HSP610
A B S T R A C T
Very long chain acyl-CoA dehydrogenase (VLCAD) deﬁciency (VLCADD) is a clinically heterogeneous disorder
of mitochondrial fatty acid β-oxidation usually identiﬁed through newborn screening. Genotype-phenotype
correlations have been deﬁned, but considerable clinical heterogeneity still exists. Symptoms are often induced
by physiological stress such as fasting or intercurrent illness, setting it as an important example of
environmental eﬀects altering clinical course in an individual with a genetic disease. However, neither the
cellular changes that predispose to this phenomenon nor the alterations it induces are well characterized. We
examined the eﬀects of fasting in a knockout mouse model to explore changes in global mitochondria protein
proﬁles in liver and to investigate the physiologically relevant changes that lead to the clinical presentations. An
isobaric tags for relative and absolute quantiﬁcation (iTRAQ) labeling approach was employed to examine
mitochondrial proteome changes in VLCAD deﬁcient compared to wild type mice in the fed and fasted states.
We identiﬁed numerous proteomic changes associated with the gene defect and fasting within relevant
metabolic pathways. Few changes induced by fasting were shared between the VLCAD deﬁcient and wild type
mice, with more alterations found in the deﬁcient mice on fasting. Particularly, fasting in the deﬁcient mice
could reverse the protective response in oxidative phosphorylation pathway seen in wild type animals. In
addition, we found that changes in chaperone proteins including heat shock protein 60 (HSP60) and 10
(HSP10) during fasting diﬀered between the two genotypes, highlighting the importance of these proteins in
VLCAD deﬁciency. Finally, the eﬀects on the liver proteome imposed by changes in fasted VLCAD deﬁcient mice
indicates that this environmental factor may be an inducer of both cellular and physiological changes.
1. Introduction
Mitochondrial fatty acid β-oxidation plays a major role in energy
production in the body, especially during fasting conditions. Fatty acids
are transferred across the mitochondrial membrane as carnitine esters
by carnitine palmitoyltransferase 1 and 2 in conjunction with the
carnitine-acylcarnitine translocase [1–3]. In the mitochondrial matrix,
the fatty acid β-oxidation cycle is initiated by ﬁve diﬀerent acyl-CoA
dehydrogenases (ACADs), leading to sequential removal of two carbons
in the form of acetyl-CoA molecules with each cycle (4–5). Electrons
are transferred from the ACADs to the respiratory chain through
complex I of the electron transfer chain or directly to coenzyme Q
(ubiquinone) by electron transfer ﬂavoprotein (ETF) and ETF ubiqui-
none oxidoreductase. Very long-chain acyl-CoA dehydrogenase
(VLCAD) is the primary ACAD active in the metabolism of straight
long chain acyl-CoAs, fueling early rounds of ketogenesis during
periods of high energy demand after hepatic glycogen depletion (6).
It is responsible for the catalysis of acyl-CoAs of 12–20 carbon in chain
length in liver, heart, and muscle.
VLCAD deﬁciency (VLCADD) has been identiﬁed in more than 400
patients world-wide. It can present with a variety of clinical symptoms
and a spectrum of severity that ranges from severe life threatening
illness in the newborn period to relatively mild disease [3,4]. It is now
diagnosed through newborn screening in many countries [5,6].
Patients who survive their initial presentation may exhibit progressive
cardiomyopathy and have a reported 75% mortality rate in the ﬁrst few
years of life [7,8]. Children with later onset symptoms can have
repeated episodes of rhabdomyolysis but are at lower risk of developing
cardiomyopathy. Sequence analysis of the ACADVL gene has revealed
correlation of mutation genotype with phenotype; however, this
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relationship is imperfect [3,4,9]. The molecular mechanisms leading to
such heterogeneity remain unknown [3,4]. We have shown that the
enzymes involved in fatty acid oxidation are arranged in a multi-
functional fatty acid oxidation complex that functionally and physically
interacts with the respiratory chain supercomplexes [10]. Thus sec-
ondary changes in other fatty acid oxidation or respiratory chain
proteins could play a role in determining clinical heterogeneity, as
could other unanticipated alterations.
The eﬀect of environmental factors on phenotype is usually
measured through epidemiological studies of individuals with some
genetic susceptibility to an exposure, but such studies are usually not
tenable in patients with rare metabolic disorders. For example, the full
scope of biological changes induced by VLCADD with or without fasting
has been impossible to characterize directly in patients. To overcome
these diﬃculties, mouse models of VLCADD oﬀer an opportunity to
explore more complicated questions than is possible in patients with
these disorders [11–16]. Two independently VLCAD deﬁcient mouse
models biochemically resembling the human deﬁciency have been
developed (16–17). Severe hypoglycemia, hypothermia, skeletal myo-
pathy, and death in one third of mice were observed in fasting mice
(18). Additional studies have documented the development of hepa-
tosteatosis in response to fasting with death after prolonged fasting
(16). An impairment in amino acid metabolism has also been shown to
lead to a reduction in gluconeogenic precursors in VLCAD deﬁcient
mice, contributing to hypoglycemia (19). A broader examination of the
biological impact of fasting on these animals at the proteomic level
should provide additional insights into the underlying pathophysiolo-
gical mechanism of gene-environmental interactions in this disorder.
2. Material and methods
Mice. VLCAD deﬁcient (C57BL/6+129svJ) and corresponding wild
type mice were purchased from Jackson Laboratory (Bar Harbor,
Maine) at age 4–5 weeks. At least 6 male mice of each genotype were
used for each paired study. For proteomics experiments in fasted mice,
each mouse was fasted 16 h prior to sacriﬁce. All animals were
sacriﬁced at 6–8 weeks of age by CO2/O2 asphyxiation according to
standard protocols approved by the University of Pittsburgh IACUC.
Liver was harvested immediately after death.
2.1. Preparation of mitochondrial protein
Freshly harvested liver mitochondria were isolated on Percoll
gradients as previously described (21). 100 µg of protein were pre-
cipitated by addition of pre-chilled acetone and collected after air
drying.
2.2. iTRAQ labeling and paired studies
Five proteomic studies were performed as previously described to
identify mitochondrial proteome changes due to either genetic deﬁ-
ciency, fasting, or both (21). Biological replicates were labeled in a
random manner to minimize possible labeling bias (Supplemental
Table 1). Labeling procedures were performed according to the
manufacturer's protocol (Applied Biosystems, Foster City, CA).
2.3. Nano-LC mass spectrometry (MS)
These experiments were performed as previously described (26).
Peptide samples were puriﬁed with strong cation exchange (SCX)
cartridges, Strata 55 µm, 70 Å (Phenomenex, Torrance, CA).
2.4. Database searches and statistics
The MS/MS spectra (RAW ﬁles) were performed as previously
described [21,22]. The MS/MS spectra (RAW ﬁles) were processed
using extract_msn.exe, February 15, 2010 (Thermo Fischer Scientiﬁc).
The MS/MS data from 10 diﬀerent fractions of peptides for each
experiment were combined to search against the IPI-mouse database
(version 3.65 with 56,775 sequences, released 10/16/2009) using
Mascot version 2.2.04 (Matrix Science, London, UK, www.
matrixscience.com) using the multidimensional protein scoring
algorithm (MudPIT) with information from Mus species only,
allowing up to two missed trypsin cleavages per protein. The full
scan tolerance was 5 ppm and MS/MS fragment tolerance was 0.75 Da.
Searches were performed allowing variable oxidation of methionine
residues (16 Da) and iTRAQ labels on tyrosine, ﬁxed modiﬁcation of
iTRAQ labels on lysine and N-terminus, and methylthionine
modiﬁcation of cysteine residues. The threshold of protein
identiﬁcation was set to a signiﬁcance of p≤0.001 corresponding to a
false discovery frequency of 0.002 searching against a decoy database.
iTRAQ values were reported for proteins with four or more measured
iTRAQ values and each included peptide scan had an expectation value
of 0.02 or below. When the identiﬁcation of a protein in an analysis
resulted in several possible protein isoforms, all of them were
considered for quantiﬁcation. In the quantitative calculations, only
protein isoforms with iTRAQ values in all analyses were included.
Proteins with a minimum of 2 labeled peptides and a mascot score of
over 60 were selected for further data analysis. In each study the
average of the eight iTRAQ values was normalized to 1.0 for all proteins
and then the data set was log (2) transformed to obtain data normally
distributed around unity. The mean value of the biological and
technical replicates for each genotypic mouse was calculated to
obtain the average fold change of a protein's production. For an
initial screening student's t-test was used to assess signiﬁcance (p≤0.
10) of the diﬀerentially regulated proteins in each study. As a second
criterion was a fold change of > 1.33 fold increase or < 0.75 fold
decrease applied. Proteins that met both criteria in 2 experiments
(experiment 1 and 2) or in one experiment (experiment 3, 4 or 5) were
included for further bioinformatics analyses.
2.5. Pathway analysis and prediction of toxicity
Pathway associations of diﬀerentially expressed proteins in deﬁ-
cient mice in either the fed or fasted state were analyzed with the
Ingenuity Pathways Analysis software (IPA; Ingenuity Systems,
Redwood City, CA; www.ingenuity.com) (21). The taxonomy was set
to “mouse”. The ﬁlters and general settings for the core analysis were
set to consider all molecules including endogenous chemicals, as well
as both direct and indirect relationships. All data sources except cell
lines were considered. Scores of 2 or higher (Fisher's exact test, p < 0.
05) having at least a 99% conﬁdence were considered as signiﬁcant. In
this analysis, we selected the top 2 networks as the most signiﬁcant.
The Global Functional Analysis (GFA) and Global Canonical Pathways
(GCP) analysis were utilized to identify the canonical pathways and
associated diseases that were related to the diﬀerentially expressed
proteins. Toxic analysis of the IPA was designed to characterize speciﬁc
organ system changes related to exposure to suspected toxins. This
function was utilized to identify patterns of altered protein expression
in VLCAD deﬁcient mice in both the fed and fasting states to assess the
secondary physiologic impact of the primary ACADVL gene defect and
fasting.
3. Results
To examine the biological impact of fasting in VLCAD deﬁcient
mice, we ﬁrst characterized liver mitochondrial proteome alterations in
VLCAD deﬁcient mice while on an ad lib diet. We next examined liver
mitochondrial proteome alterations in fasting mutant and wild type
mice. In combination, these experiments allowed us to explore the
relative contribution of the VLCADD and the environmental condition
of fasting to global proteome changes.
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3.1. VLCAD deﬁciency induced diﬀerent changes in diﬀerent feeding
states
In the fed state, 43 proteins (as deﬁned by at least 2 peptides with
p≤0.001) were classiﬁed as having at least a 30% alteration in level
between VLCADD and wild type mice (p≤0.05). A detailed description
of the identiﬁcation and quantiﬁcation information is provided in
Supplemental Table 2. If a protein has been assigned to multiple
subcellular locations by literature, a mitochondrial location for the
speciﬁc location was assumed. Comparing fasted VLCAD deﬁcient mice
to wild type animals, 54 proteins were initially screened as signiﬁcantly
altered (≤0.75 fold or ≥1.3 fold change; p≤0.05, 1 sided) out of 286
unambiguous proteins that met the identiﬁcation criteria (p≤0.001,
FDR≤0.002) (Supplemental Table 3). The level of 28 proteins was
decreased, while 24 were increased. Of note, the repertoire of proteins
diﬀering between VLCADD and wild type mice diﬀered in the fed and
fasted state, with only a few proteins altered in common under both
conditions.
3.2. Fasting eﬀects on deﬁcient and wild type mice
To explore the diﬀerential eﬀects of fasting on wild type and
VLCADD mice, we compared the proteome of mitochondria from
deﬁcient mice in the fasted vs. the fed state (Supplemental Table 4).
Then, the same comparison was done for wild type mice (Supplemental
Table 5). We found that fasting induced signiﬁcant alterations ( > 1.3-
fold increase or < 0.77-fold decrease; Student's test, 1 sided, p≤0.05,)
in 35 proteins in VLCADDmice. In wild type mice, 41 proteins changed
with fasting (data not shown). Fasting induced a diﬀerent pattern of
alterations in VLCADD mice than was seen in wild type animals,
though a limited number of changes were correlated in both genotypes.
3.3. Fasting induced changes in pathways and networks
In fed VLCAD deﬁcient vs fed wild type and fasted VLCAD deﬁcient
vs fasted wild type mice, the most highly altered Ingenuity Pathway
Analysis (IPA) network was “functions of lipid metabolism, molecular
transport and small molecule chemistry” (Figs. 1 and 2). Notably, even
though the same altered network was identiﬁed for both pairs of
analyses, the proteins comprising the network diﬀered. Two proteins,
encoded by SCP2 and NUDT7, were found decreased in deﬁcient mice
regardless of feeding status (Supplemental Figs. 1 and 2). A few
proteins, including those encoded by HSPA5, HADHA and GPX1, were
identiﬁed by network analysis to be common between fed and fasted
wild type and VLCAD deﬁcient animals, though not directly detected in
our experiments. The latter category included the nuclear receptor
PPARA, the transcription regulator PPARGC1A, and the growth factor
leptin (Figs. 1A and B, 2). These important linker proteins were also
inferred as part of the top-rated network of altered proteins in deﬁcient
mice in both feeding states (Fig. 1A and B; see Discussion). Analysis of
the canonical pathways associated with altered proteins revealed that
most of the aﬀected pathways in VLCADD mice (fed or fasted) were
deﬁned by down-regulated proteins. The pathways of fatty acid
metabolism, bile acid biosynthesis, and fatty acid elongation were
aﬀected in mitochondria from deﬁcient mice under both feeding
conditions (Supplemental Tables 1 and 2).
3.4. Gene-fasting interactions in VLCADD
Fasting in the context of VLCADD led to a diﬀerent pattern of
proteomic changes than either condition alone (Summarized in
Table 1). In wild type animals, chaperones were up-regulated by
fasting. However, in VLCADD, they were down-regulated. A compen-
satory up-regulation of the oxidative phosphorylation (OXPHOS)
pathway in VLCADD mice in the fed state was abrogated by fasting
(Figs. 2 and 3). The pathway of “mitochondrial dysfunction” was
induced by VLCADD but not fasting. In contrast, the pathways of
“branched chain amino acid metabolism including valine, leucine and
isoleucine metabolism” and “amino acid metabolism including argi-
nine, proline, tyrosine, phenylalanine and β-alanine were altered more
by fasting than the gene deﬁciency. “Synthesis and degradation of
ketone bodies” was not signiﬁcantly altered in the either fasted or fed
Fig. 1. Top-rated network of altered proteins in VLCAD deﬁcient mice under feeding and fasting states. A. Top-rated network of altered proteins in VLCAD deﬁcient mice in the fed
state. B. Top-rated network of altered proteins in VLCAD deﬁcient mice in the fasted state. This network (lipid metabolism, molecular transport and small molecule chemistry) was
generated by IPA. Red nodes indicate that the protein is up-regulated in fed VLCAD deﬁcient mice compared to fed wild type mice. Green indicates that the protein is down-regulated.
The color intensity corresponds to the degree of abundance. Proteins in white are those inferred from the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of
the protein. A solid line indicates a direct molecular interaction, and a dashed line indicates an indirect molecular interaction.
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VLCADD mice as compared to wild type, in which fasting induced
changes. In the fasted state, 3-hydroxy-3-methylgutaryl-CoA synthase
2 (HMGCS2), an enzyme that catalyzes the condensation of acetyl-CoA
and acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) was increased in VLCADD mice in the fasted state. However, the
pathway “ketone bodies production” was not globally aﬀected as
determined by IPA analysis. Proteomic changes suggestive of liver
steatosis were seen in fed VLCAD deﬁcient mice but not in fasted
animals (Fig. 4A and B).
4. Discussion
The full clinical spectrum of most diseases is determined by the
interplay of genetic and environmental factors. In this study, a mouse
model of a fatty acid oxidation defect, VLCADD, was used to char-
acterize changes in the liver mitochondrial proteome in mice that are
genetically identical except for one mutation and exposure to a speciﬁc
stressor, fasting, to identify the interaction of genes and environment
in shedding molecular insight into clinical symptoms.
The underlying mechanism of clinical and genetic heterogeneity in
VLCADD is unknown, and likely includes genetic and environmental
factors, as well as their interaction. The novelty of this study lies in the
use of animal models to screen for global biological changes related to
genotypic and environmental changes and to explore the relevance of
alterations in speciﬁc functions and pathways using well deﬁned
control groups. Multiple proteins were altered in fasted VLCAD
deﬁcient mice compared to fasted wild type mice, consistent with an
earlier report that VLCAD deﬁcient animals exhibit speciﬁc phenotype,
pathological and biochemical, under this condition [11]. However, the
relative eﬀects of fasting vs VLCADD were not well delineated. The
studies revealed that fasting had signiﬁcantly diﬀerent eﬀects in
VLCAD deﬁcient animals than in wild type ones, and furthermore that
gene-environment interactions existed, as indicated by the observa-
tions of several proteins and some associated functional groups and
0
5
10
15
Up Regulated Down Regulated
117   133  128  82    45    16  115    128   65    58   165    31    38     5    62      63    71     87    12    14     22  28
65   117   58     74    36    45    49    18     72    28    38   115    47   133    54    71    87   12    16     31   125  128
0
5
10
15
Log (p-value)
%
 o
f P
ro
te
in
s
# of Proteins
%
 o
f P
ro
te
in
s
# of Proteins
Lo
g 
(p
-
va
lu
e)
Lo
g 
(p
-
va
lu
e)
10
5
0
8
4
0
A.
B.
Fig. 2. Canonical pathways associated with altered proteins in VLCAD deﬁcient mice in the fed (A) and fasted states (B). Black indicates that the protein is down-regulated. Gray
indicates that the protein is up-regulated. The X-axis denotes the associated functions. The Y-axis represents the percentage of altered proteins among all available molecules in
Ingenuity Knowledge database associated with the functional group denoted by X-axis.
Table 1
Altered proteins in paired experiments suggestive of gene-fasting interactions.
Protein/
Enzyme
(gene
symbol)
Chaperonin
10 (Hspe1)
Cytochrome
b-c1 complex
subunit 1
(Uqcrc1)
Cytochrome
b-c1 complex
subunit 2
(Uqcrc2)
3-
ketoacyl-
CoA
thiolase
(Acaa1)
*VLCADD
(fed)
unchanged 1.37 1.23 (p=0.027) unchanged
vs
**WT (fed)
VLCADD
(fasted) vs
WT
(fasted)
−1.99 No significant
change
No significant
change
−1.61
VLCADD
(fasted) vs
VLCADD
(fed)
1.38 −1.96 −1.82 1.67
WT (fasted)
vs WT (fed)
1.65 No significant
change
No significant
change
1.48
Numbers indicate fold change, with positive ratio indicating increased fold changes of
protein production and negative ratio indicating decreased fold changes of protein
production.
p-values shown (Student's t test) in the corresponding experiments.
* VLCADD-very long chain acyl-CoA dehydrogenase deﬁcient mice.
** WT-wild type mice.
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canonical pathways (Supplemental Table 3).
An apparent gene-environment interaction was demonstrated in
the expression of chaperonin HSP10 and Cytochrome b-c1 complex
(Supplemental Table 3). Chaperonin 10 (HSPE1), a mitochondrial
chaperonin protein, was up-regulated in the fasting state in both
VLCAD deﬁcient and wild type animals as compared to the fed state.
However, in VLCADD, the down-regulation of chaperonin 10 was seen
in fasted VLCAD deﬁcient mice when compared to fasted wild type.
Thus, mitochondrial protein folding machinery appears to adjust to
environmental conditions. A similar phenomenon was seen in acetyl-
CoA acyltransferase 2 (ACAA2; also known as 3-ketoacyl-CoA thiolase.)
ACAA2 catalyzes the last step of mitochondrial fatty acid oxidation and
valine metabolism, and was up regulated in wild type and mutant mice
with fasting. However, it was down-regulated in fasted VLCAD
deﬁcient as compared to fasted wild type mice. This suggests that
fasting induced compensation in this enzyme that leads to the
increased production of acetyl-CoA for citric acid cycle activity under
conditions of energy was depletion was abrogated by VLCADD.
Changes in cytochrome b-c1 complex subunits (QCRr1 and QCR6
in Supplementary Table 2; QCR7 in Supplementary Table 3) or the
respiratory chain were also induced by fasting in VLCADD. Fasting
only impacts cytochrome b-c1 levels in the VLCADD mice. Cytochrome
b-c1 complex is the intrinsic membrane protein that catalyzes the
oxidation of ubihydroquinone and the reduction of cytochrome c in
mitochondrial respiratory chains. Fasting only impacts cytochrome b-
c1 levels in the VLCAD deﬁcient mice, suggesting a compensatory eﬀect
for the primary deﬁciency induced by fasting. This ﬁnding further
emphasizes a more pronounced eﬀect on energy metabolism in
response to the defect in fatty acid oxidation. It should be noted that
additional changes could still be present in the fasted, VLCAD deﬁcient
animals due to the diﬃculty in detecting proteins with low levels of
expression with iTRAQ.
In total, our ﬁndings indicate that an ACADVL gene defect leads not
only to alterations in the proteome compared to wild type animals, but
also how that proteome changes in response to environmental factors
(Fig. 5). Speciﬁcally, VLCADD mice respond diﬀerently to fasting than
do wild type animals. Canonical pathway analysis identiﬁed signiﬁcant
changes in fasting animals of both genotypes. In contrast, fewer
diﬀerences were seen between the changes in deﬁcient mice and in
wild type mice, indicating that the changes in these pathways were
related to fasting but not genotype. The results from this proteomic
study conﬁrm that the normal ketogenic response to fasting remains
intact in the face of VLCADD. Although expression of some individual
proteins changed, association analysis showed that in total, the path-
way of ketone bodies production was not signiﬁcantly up regulated in
fasting deﬁcient animals as it was in wild type animals. The pathways of
amino acid metabolism, especially branched chain amino acid meta-
bolism, as well as carbohydrate and fatty acid metabolism were more
Fig. 3. Canonical pathways associated with fasting in VLCAD deﬁcient mice and wild type mice. A. Wild type and B. VLCAD deﬁcient mice. This bar chart shows the signiﬁcance of
canonical pathways associated with fasting. The left Y-axis displays the signiﬁcance and corresponds to the height of the bars; the right Y-axis displays the ratio and represents the
percentage of altered proteins among all available molecules in Ingenuity Knowledge database associated with the functional group denoted by X-axis.
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signiﬁcantly altered in the fasted state than in the fed state in VLCAD
deﬁcient mice suggesting a more global derangement in cellular
metabolism in fasting mutant animals. These ﬁndings are consistent
with recent metabolic studies on VLCADD animals [16–21]. The
greatest diﬀerences were in the OXPHOS and citric acid cycle pathway
and bile acid synthesis. An increased pattern in OXPHOS identiﬁed in
fed VLCAD deﬁcient mice disappeared when they were fasted. The
OXPHOS pathway was unchanged when wild type mice were fasted.
However, fasting induced the down-regulation of several proteins in
OXPHOS in mutant animals. Thus, a presumed compensatory change
in the mutant animals appears to be negated during fasting, and may
play a role in the development of symptoms..
Proteins in the most signiﬁcantly altered constructed network in fed
and fasted VLCAD deﬁcient mice were linked by several well described
transcription factors inferred from the IPA knowledge database. They
included nuclear receptors PPARA (peroxisomal proliferator-activated
receptor A), PPARG, PPARGC1A, and NR3C1 (nuclear receptor sub-
family 3, group C). These nuclear receptors in the molecular play a
more general role in regulating energy metabolism and their upregula-
tion suggests a compensatory response to a secondary energy deﬁ-
ciency in VLCADD. A similar relationship has been demonstrated in
one previous study that showed that expression of the PPARA and
PPARG genes were increased in VLCAD deﬁcient mice in the fasted
state, but was unchanged or slightly reduced in the fed state (30). 3-
Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the rate-limit-
ing enzyme for cholesterol synthesis and is regulated via a negative
feedback mechanism mediated by sterols and non-sterol metabolites
(31). Leptin (LEP) is secreted by white adipocytes and plays a major
role in the regulation of body weight, but has been reported not to
aﬀect fatty acid oxidation (32). Both molecules were inferred on the
basis of relationships with other molecules incorporated in the IPA
knowledge database to participate in regulating changes in the function
of lipid metabolism in VLCADD mice. Further studies are needed to
demonstrate their roles in determining clinical symptoms in FAODs.
The clinical relevance to secondary changes associated with a
Acadvl gene defect was further evaluated through the toxicity analysis
function in the IPA software to provide additional insight into the
pathologic alterations induced by Acadvl gene defect and fasting. Mice
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Fig. 4. A. Prediction of pathological changes related to VLCAD deﬁciency in fasted and fed states in mice. Black denotes toxicity predicted by changed proteins in fasted VLCAD deﬁcient
mice compared to fasted wild type mice. Gray shows toxicity predicted by changed proteins in fed VLCAD deﬁcient mice compared to fasted wild type mice. Y-axis: signiﬁcance of toxicity
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VLCADD Fatty acid oxidation 
Lipid transport 
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Mito stress response 
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Fasting Mito stress response 
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Fig. 5. Summary of the functional eﬀects of fasting and VLCAD deﬁciency in mice. Up-
regulated functions are depicted in red, and down-regulated functions are in blue.
Fasting induced a shared upregulation of the mitochondrial stress response in wild type
and deﬁcient animals. Compensatory changes in fatty acid oxidation in wild type animals
was not seen in deﬁcient animals, which instead showed increased oxidative phosphor-
ylation (OXPHOS) and a pattern of protein changes consistent with liver steatosis. The
adaptive response of deﬁcient animals was diﬀerent compared to wild type with
decreases in a variety of intermediary metabolic pathways and a pattern consistent with
cardiac stress and cardiomyopathy.
W. Wang et al. Biochemistry and Biophysics Reports 8 (2016) 333–339
338
deﬁcient for VLCAD develop hepatic steatosis upon fasting (16). They
also accumulate microvesicular lipids and demonstrate marked mito-
chondrial proliferation in heart (17). Both phenotypes are seen in the
human deﬁciency to some extent (7). Our toxicity analysis using the
IPA software indeed identiﬁed a pattern of protein changes predictive
of liver damage (steatosis) in VLCAD deﬁcient mice under both feeding
states. While, the liver steatosis through the prediction of the patho-
logical changes of secondary proteomic changes was suggestive in
VLCAD deﬁcient mice and wild type mice due to fasting. Further
analysis of fasting eﬀects alone on deﬁcient mice and wild type mice
indicates that the liver steatosis was slightly more exaggerated in wild
type mice (Supplemental Tables 1 and 2). However, fasting is also
associated with liver hyperplasia/hypersteatohepatitis in VLCAD deﬁ-
cient mice suggesting that the occurrence of liver steatosis in VLCADD
may not be solely due to fasting but as a result of the interaction of
Acadvl gene defect and fasting. This pattern of protein changes
suggesting liver dysfunction implies that avoidance of fasting may
not alter the liver dysfunction in those patients with VLCADD. The
correction of liver dysfunction may be achieved only or at least by
treatment of the gene deﬁciency. The physiologic implication of ETHE1
(ethylmalonic encephalopathy) gene expression is unclear; however, it
has been reported to be altered in response to metabolic state in obese
rats (25).
In conclusion, some of the changes of fasting in VLCADD reﬂect
known physiologic and pathologic alterations previously characterized
in VLCAD deﬁciency and fasting. Others provide novel insights into
possible new secondary eﬀects of the defect and mechanisms for
fasting-gene defect interaction in this disease. The results identify an
aberrant fasting response in VLCAD deﬁcient mice and the secondarily
altered proteins in these mice deﬁne interactions of both genes and
speciﬁc environmental interactions with the Acadvl gene.
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